使用[(18)F]FAZA-PET进行纵向肿瘤缺氧成像可对纳米脂质体伊立替康（nal-IRI）治疗活性进行早期预测。
Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity.
作者信息
Zheng Jinzi, Klinz Stephan G, De Souza Raquel, Fitzgerald Jonathan, Jaffray David A
机构信息
TECHNA Institute for the Advancement of Technology for Health, University Health Network, 101 College Street, Rm 7-302, Toronto, Ontario, M5G 1L7, Canada.
Department of Radiation Physics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
出版信息
EJNMMI Res. 2015 Dec;5(1):57. doi: 10.1186/s13550-015-0135-x. Epub 2015 Oct 19.
BACKGROUND
Non-invasive measurement of tumor hypoxia has demonstrated potential for the evaluation of disease progression, as well as prediction and assessment of treatment outcome. [(18)F]fluoroazomycin arabinoside (FAZA) positron emission tomography (PET) has been identified as a robust method for quantification of hypoxia both preclinically and clinically. The goal of this investigation was to evaluate the feasibility and value of repeated FAZA-PET imaging to quantify hypoxia in tumors that received multi-dose chemotherapy.
METHODS
FAZA-PET imaging was conducted over a 21-day period in a mouse xenograft model of HT-29 human colorectal carcinoma, following multi-dose chemotherapy treatment with irinotecan (CPT-11) or nanoliposomal irinotecan (nal-IRI, MM-398).
RESULTS
Tumors treated with 10 mg/kg nal-IRI maintained significantly lower levels of hypoxia and smaller hypoxic fractions compared to tumors that received 50 mg/kg CPT-11. Specifically, differences in FAZA uptake were detectable 9 days before any significant differences in tumor volume were observed between the treatment groups.
CONCLUSIONS
These findings highlight the potential use of FAZA-PET as an early marker of treatment response following multi-dose chemotherapy.
背景
肿瘤缺氧的非侵入性测量已显示出在评估疾病进展以及预测和评估治疗结果方面的潜力。[18F]氟阿糖胞苷（FAZA）正电子发射断层扫描（PET）已被确定为一种在临床前和临床中量化缺氧的可靠方法。本研究的目的是评估重复进行FAZA-PET成像以量化接受多剂量化疗的肿瘤中缺氧情况的可行性和价值。
方法
在用伊立替康（CPT-11）或纳米脂质体伊立替康（nal-IRI，MM-398）进行多剂量化疗后，在HT-29人结肠直肠癌小鼠异种移植模型中于21天内进行FAZA-PET成像。
结果
与接受50mg/kg CPT-11的肿瘤相比，用10mg/kg nal-IRI治疗的肿瘤维持了显著更低水平的缺氧和更小的缺氧分数。具体而言，在观察到治疗组之间肿瘤体积有任何显著差异之前9天，就可检测到FAZA摄取的差异。
结论
这些发现突出了FAZA-PET作为多剂量化疗后治疗反应早期标志物的潜在用途。
Zotero 插件